Long-Term Safety, Efficacy of Sunitinib for Gastrointestinal Tumors Confirmed
the Cancer Therapy Advisor take:
The long-term safety and efficacy of sunitinib in patients with advanced gastrointestinal stromal tumor (GIST) was confirmed in a large international population, according to a study published online in the journal Cancer.
In this study, the imatinib-resistant/intolerant patients were given an initial dosage of sunitinib 50 mg daily in 6-week cycles—4 weeks on treatment and 2 weeks off treatment. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.0.
Overall, the study included 1,124 patients in the intent-to-treat population, 15% of which had a baseline Eastern Cooperative Oncology Group performance status greater than or equal to 2.
Median values for treatment duration and tumor progression were analyzed [7.0 months and 8.3 months (95% CI: 8.0, 9.4 months), respectively]. The median overall survival was found to be 16.6 months (95% CI: 14.9, 18.0 months), with 36% of patients alive at the time of analysis.
Patients that had a modified initial dosing schedule had a longer median overall survival of 23.5 months compared with patients who were strictly treated using the initial dosing schedule (OS 11.1 months).
Treatment-related grade 3 and 4 adverse events included hand-foot syndrome (11%), fatigue (9%), neutropenia (8%), hypertension (7%), thrombocytopenia (6%), and those associated with cardiac function (e.g., congestive heart failure) (≤1%).
Long-term safety and efficacy of sunitinib in patients with advanced gastrointestinal stromal tumor was confirmed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer